RecruitingNot a traditional drug phaseobservationalRules rewrite

Not a traditional drug phase: testing Infliximab for Inflamatory Bowel Disease

This retrospective cohort study aims to compare the how well it works of different biologics in preventing postoperative endoscopic recurrence in Crohn's disease (CD). It plans to include 198 adult patients who underwent bowel resection and initiated prophylactic biologic therapy between January 1, 2015, and April 1, 2025.

Official registry: https://clinicaltrials.gov/study/NCT07694674 · Shanghai 10th People's Hospital · enrollment listed as 198

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 198 people at Shanghai. Taking part typically means an infusion or injection of a biologic plus check-ins.

Official title (unrewritten)

Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease

Interventions: Infliximab, Adalimumab, Vedolizumab, Ustekinumab (UST)

Primary outcome (registry wording): Endoscopic recurrence rate

Who it is for (from inclusion criteria)

Ages 18 Years to 85 Years
Diagnosis of Crohn's disease according to the European Crohn's and Colitis Organisation (ECCO) guideline criteria, based on clinical, laboratory, endoscopic, radiologic, and histopathologic findings
Underwent Crohn's disease-related intestinal resection, including ileocolonic resection, segmental small bowel resection, or segmental colonic resection
Initiated postoperative prophylactic biologic therapy within 6 weeks after surgery
Maintained postoperative prophylactic biologic therapy for at least 3 to 6 months
Completed at least one evaluable postoperative ileocolonoscopy within 6 to 12 months after surgery for assessment of the Rutgeerts score, or had available clinical, radiologic, ultrasonographic, or laboratory data for evaluation of clinical recurrence

Who the registry excludes

Diagnosis of other intestinal diseases, including intestinal Behçet's disease, ulcerative colitis, intestinal tuberculosis, or intestinal malignancy
Intestinal surgery mainly performed for non-IBD conditions, such as intestinal malignancy
No postoperative endoscopic evaluation within 6 to 12 months after surgery, or endoscopic quality insufficient for Rutgeerts score assessment, and lack of adequate clinical, radiologic, ultrasonographic, or laboratory data for recurrence assessment
Irregular use of postoperative prophylactic therapy due to severe comorbidities, serious infection, or other reasons, making treatment how well it works difficult to evaluate
Other conditions considered by the investigators to be inappropriate for inclusion

Contact

No central phone on the registry card. Use the official listing to reach a site.

Sites listed on ClinicalTrials.gov

1 listed

The Tenth People's Hospital of Shanghai — Shanghai, Shanghai Municipality, China (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseLeuven, Vlaams-Brabant

Not a traditional drug phase: Sample collection for IBS

Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.

NCT02421705 · Official ClinicalTrials.gov record · KU Leuven

RecruitingPhase 1 / Phase 2Bethesda, Maryland

Phase 1 / Phase 2: testing Vorinostat for Crohn's Disease

Background: Crohn s disease (CD) is an inflammatory bowel disease. Symptoms may include diarrhea, abdominal pain, fatigue, weight loss and malnutrition.

NCT03167437 · Official ClinicalTrials.gov record · National Institute of Allergy and Infectious Diseases (NIAID)

RecruitingNot a traditional drug phaseHouston, Texas

Not a traditional drug phase: testing Ustekinumab for Crohn Disease

This study wants to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).

NCT04372108 · Official ClinicalTrials.gov record · Janssen Scientific Affairs, LLC

FAQ about this NCT record

Is NCT07694674 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07694674?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07694674?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary